Allergan Posts Solid 1Q, With Revenue and Margin Improvements Expected Over the Rest of the Year
We plan to make a few adjustments to our Allergan model to reflect timing of the recent LifeCell and Zeltiq acquisitions in addition to slightly higher operating costs, but the company’s first-quarter results broadly met our expectations. We’re keeping our fair value estimate for Allergan unchanged, and we continue to think management’s recent acquisitions help reinforce the firm’s wide moat, particularly in its attractive aesthetics business. Management slightly raised its year-end outlook to r...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.